drugset / Trial / NCT06520176

Summary

This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.

Timeline

Start
2024-08
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified 1 g
Comparator Cyclophosphamide Other / unclassified 2 g
Subject Cytarabine Small molecule 200 unknown
Subject Etoposide Small molecule 75 mg/m2
Subject G-CSF Unknown 5 ug/kg Subcutaneous
Subject Pegfilgrastim Protein / enzyme biologic 6 mg